IMVT - NASDAQ
Immunovant, Inc.
$31.15
+1.2%Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of myasthenia gravis and thyroid eye disease, as well as completed initiation of Phase II clinical trials for the treatment of warm autoimmune hemolytic anemia. The company was incorporated in 2018 is headquartered in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd.
At a Glance
Live SnapshotNo Dividend Yield Data
IMVT has not reported any dividend yield values in the available annual periods.
No Dividend Payout Ratio Data
IMVT has not reported any dividend payout ratio values in the available annual periods.
No Net Dividends Paid Data
IMVT has not reported any net dividends paid values in the available annual periods.
Immunovant, Inc. Dividend History
IMVT Dividend Payment History
| Declaration | Ex-Date | Payment Date | Dividend | Adjusted | Frequency | Growth |
|---|---|---|---|---|---|---|
| No dividend payment history available | ||||||
Immunovant, Inc. Payout Ratio Analysis
Dividend Sustainability Analysis
Payout Ratio
Conservative payout with excellent safety margin. Company retains significant earnings for growth, acquisitions, or building cash reserves. Dividend is highly sustainable.
FCF Payout Ratio
Negative free cash flow while paying dividends is a major red flag. Company burning cash and cannot sustain dividend without external financing.
Sustainability
Dividend appears unsustainable based on current metrics. High probability of reduction or elimination. Proceed with caution.
Related Guides
Continue your IMVT research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.